Patents Assigned to Universite de Montpellier
-
Patent number: 10801040Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the peripheral nervous system of a subject in need thereof comprising the step of transducing a peripheral nerve of the subject with an amount of an AVV9 vector containing the polynucleotide of interest.Type: GrantFiled: July 6, 2016Date of Patent: October 13, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE PARIS-SUD, COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ DE MONTPELLIERInventors: Patrick Aubourg, Nicolas Tricaud, Benoît Gautier
-
Patent number: 10787493Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.Type: GrantFiled: June 14, 2019Date of Patent: September 29, 2020Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITË DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
-
Patent number: 10781452Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.Type: GrantFiled: September 13, 2018Date of Patent: September 22, 2020Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIERInventor: Jean Valmier
-
Patent number: 10777833Abstract: An electrolyte membrane including (i) a porous mat of nanofibres, wherein the nanofibres are composed of a non-ionically conducting heterocyclic-based polymer, the heterocyclic-based polymer comprising basic functional groups and being soluble in organic solvent; and (ii) an ion-conducting polymer which is a partially- or fully-fluorinated sulphonic acid polymer. The porous mat is essentially fully impregnated with ion-conducting polymer, and the thickness of the porous mat in the electrolyte membrane is distributed across at least 80% of the thickness of the electrolyte membrane. Such a membrane is of use in a proton exchange membrane fuel cell or an electrolyser.Type: GrantFiled: August 4, 2015Date of Patent: September 15, 2020Assignees: Johnson Matthey Fuel Cells Limited, Centre National de la Recherche Scientifique, Universite de MontpellierInventors: Deborah Jones, Jacques Roziere, Sara Cavaliere, Surya Subianto, Sarah Burton
-
Publication number: 20200283432Abstract: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.Type: ApplicationFiled: November 17, 2016Publication date: September 10, 2020Applicants: AGV Discovery ENSCM, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite de MontpellierInventors: Jean-François GUICHOU, Cédric BORIES, Clément GEOFFROY, Charline DUQUENNE, Muriel GELIN, Gilles LABESSE, Yannick BESSIN, Loic MATHIEU
-
Patent number: 10758615Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.Type: GrantFiled: January 14, 2016Date of Patent: September 1, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Couvineau, Thierry Voisin, Pascal Nicole, Bruno Robert, Pierre Martineau, Myriam Chentouf
-
Patent number: 10758548Abstract: The present invention relates to methods and pharmaceutical compositions for treating peripheral demyelinating diseases. In particular the present invention relates to a method of treating a peripheral demyelinating disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of VDAC1 activity or expression.Type: GrantFiled: May 19, 2016Date of Patent: September 1, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIERInventors: Nicolas Tricaud, Sergio Gonzalez
-
Patent number: 10731218Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods for determining the ovarian reserve and ovarian function by determining the level of cell-free nucleic acids or the level of a miRNA species selected from miR_30_a or miR_140 or let_7_b or miR_191 or miR_320_a or miR_21 or miR_30_d or miR_574_3p. The method may also be used in predicting the efficacy of controlled ovarian hyperstimulation.Type: GrantFiled: June 20, 2019Date of Patent: August 4, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIERInventors: Samir Hamamah, Sabine Traver, Elodie Scalici
-
Publication number: 20200239444Abstract: A compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.Type: ApplicationFiled: April 15, 2020Publication date: July 30, 2020Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Pierre ROUX, Florence MAHUTEAU, Romain NAJMAN, Gilles GADEA, Jamal TAZI, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC
-
Patent number: 10718770Abstract: The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).Type: GrantFiled: February 19, 2016Date of Patent: July 21, 2020Assignees: ABIV AX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier Scherrer, Aude Garcel, Noelie Campos, Jamal Tazi, Audrey Vautrin, Florence Mahuteau, Romain Najman, Pauline Fornarelli
-
Patent number: 10717724Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.Type: GrantFiled: April 5, 2018Date of Patent: July 21, 2020Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
-
Patent number: 10716506Abstract: A prosthetic implant includes a cavity that opens at an outer face of the prosthetic implant, the cavity forming a housing for receiving: a printed circuit including a radio tag; and a cover which closes the cavity at least partially when positioned on the implant in a so-called closed position, the radio tag and printed circuit being removably housed in the cavity.Type: GrantFiled: July 20, 2017Date of Patent: July 21, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, BONETAGInventors: Arnaud Vena, Brice Sorli, Stéphan Cahuzac, Stéphane Naudi
-
Patent number: 10709687Abstract: The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of: (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity, (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, and (iii) establishing a daily dosage range per human adult per day wherein (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.Type: GrantFiled: June 8, 2017Date of Patent: July 14, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, BIODOL THERAPEUTICSInventor: Jean Valmier
-
Patent number: 10704104Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: GrantFiled: October 20, 2015Date of Patent: July 7, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Thierry, Safia El Messaoudi
-
Patent number: 10689384Abstract: The invention relates to imidazo[1,2-a]quinoxaline compounds of formula (I) for the treatment of cancer, the pharmaceutical compositions comprising said chemical compounds, and the therapeutic uses thereof.Type: GrantFiled: December 30, 2015Date of Patent: June 23, 2020Assignees: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS), Axlr, Satt du Languedoc RoussillonInventors: Carine Deleuze-Masquefa, Pierre-Antoine Bonnet, Pierre Cuq, Cindy Patinote
-
Patent number: 10683284Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.Type: GrantFiled: July 31, 2018Date of Patent: June 16, 2020Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Julien Santo
-
Patent number: 10676791Abstract: The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSR v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSg oType: GrantFiled: July 27, 2015Date of Patent: June 9, 2020Assignees: INSERM(INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Jerome Moreaux, Guillaume Cartron, Caroline Bret, Angelos Constantinou, Philippe Pasero
-
Publication number: 20200172525Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.Type: ApplicationFiled: February 11, 2020Publication date: June 4, 2020Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal TAZI, Florence MAHUTEAU, Romain NAJMAN, Didier SCHERRER, Julien SANTO
-
Patent number: 10662481Abstract: The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patieType: GrantFiled: March 20, 2015Date of Patent: May 26, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIERInventors: Jérôme Moreaux, Bernard Klein
-
Publication number: 20200157365Abstract: A process for preparing a crosslinked fluoropolymer film, including the successive steps of: (1) formulating an ink containing: (a) the product of the reaction of triethylamine with at least one fluorinated copolymer obtained by radical copolymerization of monomers including: (i) vinylidene fluoride (VDF), (ii) trifluoroethylene (TrFE), (iii) at least one chlorinated monomer of formula —CXCl?CX1X2 where X, X1 and X2 independently denote H, F or CF3, wherein at most one of X, X1 and X2 denotes CF3; (b) at least one crosslinking agent; (c) at least one photoinitiator; and (d) at least one organic solvent; (2) applying said ink in film form to a substrate; and (3) UV-irradiating said film. Also, the film capable of being obtained according to this process, and also to the uses thereof, in particular in the manufacture of (opto)electronic devices and more particularly in the manufacture of a gate dielectric layer in a field-effect transistor.Type: ApplicationFiled: July 17, 2018Publication date: May 21, 2020Applicants: ARKEMA FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Universite De Montpellier, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Thierry LANNUZEL, Fabrice DOMINGUES DOS SANTOS, Thibaut SOULESTIN, Vincent LADMIRAL, Bruno AMEDURI